Novo Nordisk says two in three patients on its experimental obesity shot CagriSema lost at least 5% of their body weight within eight weeks, and that this group went on to lose 25.4% on average by week 68. The figures come from a fresh look at a finished trial, not a new study, and they arrive weeks before US regulators are due to decide whether the drug can be sold there.
CagriSema at ObesityWeek 2026
- 25.4% average weight loss at week 68 among early responders in REDEFINE 1
- 67.8% share of CagriSema patients who counted as early responders
- Q4 2026 when Novo expects a US decision on the drug
Novo went back to a finished trial
Novo released the analysis on Sunday 15 November at ObesityWeek 2026, a medical conference in Washington, DC. It returns to REDEFINE 1, a 68-week phase 3 trial in 3,417 adults with obesity or overweight, at least one related health problem and no type 2 diabetes.
CagriSema is a once-weekly injection that pairs semaglutide with cagrilintide, a long-acting version of the hormone amylin. According to Novo, the two molecules cut hunger and make people feel fuller, so they eat less.
This time the company sorted patients on the 2.4mg/2.4mg dose by how quickly the drug took hold. An early responder was anyone who had lost at least 5% of their body weight by week 8. Everyone else counted as a delayed responder.
Novo Nordisk: share price, chart and news


Fast starters kept losing weight
Of the patients analysed, 67.8% cleared the eight-week bar, and Novo said women were more likely than men to respond early. By week 68 they had lost 25.4% of their weight on average, and almost three in four had shed a fifth or more. The slower group still lost 17.8%.
| Group | Patients | Loss at week 8 | Loss at week 68 | Lost 20% or more |
|---|---|---|---|---|
| Early responders | 1,367 | 7.8% | 25.4% | 73.3% |
| Delayed responders | 649 | 3.4% | 17.8% | 37.2% |
The figures cover only the time people were taking the drug.
"Obesity is a chronic disease, and people respond to treatment differently and over different timeframes," said Martin Holst Lange, Novo's chief scientific officer and head of research and development.
A second analysis of the same trial asked how patients felt about daily life. At week 68, 73.1% of those on CagriSema reported a meaningful improvement in physical function, such as carrying out everyday activities, against 49.1% on placebo. For psychosocial function, which covers self-esteem and comfort in social situations, the figures were 69.0% and 42.1%. Both comparisons assume every patient stayed on treatment.
The analysis comes with big caveats
Novo itself calls the early-responder figures post hoc and hypothesis-generating: the question was asked after the trial had finished, so the answer can suggest ideas for future studies but cannot prove them. Dr W. Timothy Garvey of the University of Alabama at Birmingham, an author of the analysis, was blunt.
"These values are hypothesis-generating, and they are not the basis for changing clinical decision-making," he said in the company's release.
Side effects were common. In REDEFINE 1, 79.6% of patients on CagriSema reported gastrointestinal problems, against 39.9% on placebo. Nausea affected 55% of CagriSema patients, against 12.6% on placebo, while 30.7% had constipation and 26.1% vomited. Novo said these events were mostly short-lived and mild to moderate, but 5.9% of CagriSema patients stopped treatment because of side effects, compared with 3.5% on placebo.
What the new figures do not show
- They do not come from a new trial: they re-slice REDEFINE 1, which has already reported
- They cannot tell a doctor in advance which patient will respond early
- They do not change the result of the head-to-head trial against tirzepatide
CagriSema trailed tirzepatide in a direct contest
On 23 February Novo reported that REDEFINE 4, an open-label 84-week trial in 809 people, had missed its main goal: showing that CagriSema was not meaningfully worse than tirzepatide 15mg, its strongest rival. If everyone had stuck with treatment, CagriSema patients lost 23.0% of their weight against 25.5% on tirzepatide. Counting everyone, whether or not they kept going, the figures were 20.2% and 23.6%.
Novo also brought lower doses to Washington. REDEFINE 9 tested 1.7mg/1.7mg and 1.0mg/1.0mg in 309 adults, and Novo announced the results on Saturday 14 November alongside publication in The Lancet Diabetes & Endocrinology. If all patients had stayed on treatment, they lost 20.7% and 21.0% after 68 weeks, against 2.0% on placebo. Counting everyone, the losses were 19.4% and 18.6%, against 4.6%.
A US decision is due this quarter
Novo filed CagriSema 2.4mg/2.4mg with the US Food and Drug Administration in December 2025 and expects a decision in the fourth quarter of 2026. The filing rests on the REDEFINE 1 and REDEFINE 2 trials, the company said in February. The drug is not approved in the US, and Novo stresses that its safety and efficacy have not been established.
In February Novo also said REDEFINE 11, a trial designed to measure CagriSema's full weight-loss potential, should report in the first half of 2027.
Questions and answers
What did Novo Nordisk show about CagriSema at ObesityWeek 2026?
In a post hoc analysis of the REDEFINE 1 trial, 67.8% of patients on CagriSema lost at least 5% of their weight by week 8. That group lost 25.4% on average by week 68, against 17.8% for slower responders.
Is CagriSema approved in the US?
No. Novo Nordisk filed CagriSema with the FDA in December 2025 and expects a decision in the fourth quarter of 2026.
How does CagriSema compare with tirzepatide?
In the REDEFINE 4 head-to-head trial, CagriSema produced 23.0% average weight loss against 25.5% for tirzepatide over 84 weeks, if all patients stayed on treatment. It failed to show it was not meaningfully worse.
Sources
- Novo Nordisk (PR Newswire): Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek 2026
- Novo Nordisk (PR Newswire): Novo's investigational CagriSema demonstrated 21% average weight loss with lower doses in the REDEFINE 9 trial
- Novo Nordisk: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved








